Skip to content
Riskpilot
← Back to search
Sign in
Get full access
ONCORAL PHARMA ApS
APS
Active
Advertising protection
CVR 35481214
Amaliegade 6, 1256
København K
Research and experimental development on natural sciences and engineering
·
NACE 7210
Est. 2013 · 12 years old
0 employees
Monitor
Share
Denmark
/
Companies
/
Research and experimental development on natural sciences and engineering
/
ONCORAL PHARMA ApS
Overview
Financials
People & ownership
Related companies
Loading company…
People & ownership
Management
Actively employed in the business
Name
Role
Member since
Current (1)
MO
Magnus Olafsson Corfitzen
Chief Executive Officer
Chief Executive Officer
2017
Former (1)
PG
Peter Gudmund Nielsen
Management
Management
2013 – 2017
Board of directors
Non-executive oversight
Name
Role
Member since
Former (3)
MM
Mette Munch
Chairman
Chairman
2015 – 2017
JF
Jørn Frederik Falch
Chairman
Chairman
2013 – 2015
AV
Ann Vivian Fullerton
Board of Directors
Board of Directors
2013 – 2017
Shareholders
As of last annual report
Shareholder
Type
Ownership
Votes
Since
Ascelia Pharma AB
Individual
100%
100%
2017
Styrelsen for Forskning og Uddannelse
Company
20–24.99%
20–24.99%
2016
PEBEAN HOLDING ApS
Company
66.67–89.99%
66.67–89.99%
2013
Uddannelses- og Forskningsstyrelsen
Company
20–24.99%
20–24.99%
2017
CAPNOVA A/S
Company
5–9.99%
5–9.99%
2016
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive.
Learn more
.
More on ONCORAL PHARMA ApS
Overview →
Headline figures, risk assessment and company summary
Financials & key figures →
Revenue, EBITDA, balance sheet and 5-year trend
Related companies →
Corporate hierarchy, parent and subsidiary network
